Tolerance and Activity of Oxaliplatin with Protracted Topotecan Infusion In Patients With Previously Treated Ovarian Cancer. A phase I study

BACKGROUND: Topotecan 14-day infusion combined with cisplatin was highly active in ovarian cancer, but too myelosuppressive. We therefore sought to evaluate the feasibility of substituting oxaliplatin for cisplatin to improve safety. METHODS: Ovarian and primary peritoneal cancer patients, pre-treat...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Hochster, Howard, Chen, Thomas T., Lu, Janice M., Hills, Day, Sorich, Joan, Escalon, Juliet, Ivy, Percy, Liebes, Leonard, Muggia, Franco
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2008
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3572735/
https://ncbi.nlm.nih.gov/pubmed/18191187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2007.11.017
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items